# Biocon gets nod to sell Yesintek in 9 more markets 2026-10-26T04:42:02+00:00 | Business & Economy | Indian Opinion Desk Corroboration: 2 independent outlets Biocon Ltd has secured market access for Yesintek, its proposed biosimilar to Stelara, in nine additional countries through a licence agreement with Janssen Sciences Ireland. The deal covers Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan with immediate effect. The agreement builds on earlier settlements that gave Yesintek entry to the US, Europe, the UK, Canada and Japan. Stelara, owned by Johnson & Johnson's Janssen unit, had global sales of $6.08 billion in 2025. Biocon said the expanded access will offer an affordable treatment option for autoimmune diseases including Crohn's disease and plaque psoriasis. Product launches in each market remain subject to regulatory approval. Financial terms were not disclosed. ## Indian Opinion Analysis Both outlets deliver straight news coverage of Biocon's licence deal with Janssen, leading with the same facts: the nine new markets and the clinical details of Yesintek. Business Standard adds a caveat about regulatory approvals and notes financial terms were undisclosed, giving a slightly more cautious read, while CNBC-TV18 front-loads the share-movement angle in its headline but keeps the body purely factual. The difference is negligible, identical event, no slant divergence. The key open point is the absence of specific launch dates and regulatory filing status for the new markets, which will determine actual commercial impact. That awaits company disclosures. ## Coverage Coverage: 2 sources, 2 neutral - cnbctv18.com (neutral report) neutral-report, share-price-led headline but body factual - business-standard.com (neutral report) neutral-report, adds regulatory caveat and undisclosed terms This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry. Tags: Biocon, Janssen, Johnson & Johnson, Yesintek Canonical: https://indianopinion.org/biocon-gets-nod-to-sell-yesintek-in-9-more-markets/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/biocon-gets-nod-to-sell-yesintek-in-9-more-markets/#story-in-brief How this brief was made: an AI model read the reports linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. Stance labels are editorial classifications of how each outlet framed this story, assigned by the same model, not ratings of the outlets. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/